Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of patients and evaluation of oral drug treatment for relapsing-remitting multiple sclerosis
RBR-9x6yxbvCompleted
- Sponsor
- Universidade Federal de Mato Grosso do Sul
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of teriflunomide, dimethyl fumarate and fingolimod in multiple sclerosis (MS) (2 cohorts), sponsored by Universidade Federal de Mato Grosso do Sul. Started Jun 2021; status: completed.
02
Drugs
teriflunomidedimethyl fumaratefingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on RBR-9x6yxbv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9x6yxbv.